Clinical Trial Update: Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas [Phase 2]

View source ↗

Summary

Phase 2 trial investigating collagen cross-linking with UVA in asymmetric corneas (keratoconus) was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Diseases
• Eye Diseases
• Keratoconus

Drugs mentioned

• Collagen cross-linking with ultraviolet-A (not specified)

Snippet

Sponsor: Cxlusa | Conditions: Keratoconus, Corneal Diseases | Phase 2 | Status: TERMINATED | Results posted: 2022-01-12